Diabetic nephropathy pathophysiology: Difference between revisions

Jump to navigation Jump to search
 
(45 intermediate revisions by 5 users not shown)
Line 1: Line 1:
{| class="infobox mw-collapsible" id="floatvideo" style="position: fixed; top: 65%; width:361px; right: 10px; margin: 0 0 0 0; border: 0; float: right;"
| Title
|-
|-
| {{#ev:youtube|https://https://www.youtube.com/watch?v=LtdWg4ygm_E&t=9s|350}}
|-
|}
__NOTOC__
__NOTOC__
{{Diabetic nephropathy}}
{{Diabetic nephropathy}}
{{CMG}}; {{AE}} {{AN}}
{{CMG}}; {{AE}}{{DN}}


==Overview==
==Overview==
Thickening of [[glomerular basement membrane]], accumulation of eosinophilic material in the mesangium and intraglomerular hypertension are the major pathophysiologic changes taking place in the nephrons in long standing [[diabetes mellitus]].
The hallmark of diabetic nephropathy is [[Mesangial cell|mesangial]] expansion. Nonetheless, diabetic nephropathy is characterized by the presence of abnormalities in the glomeruli, such as glomerular hypertrophy, in the [[tubules]] and [[interstitium]], such as tubular atrophy and interstitial fibrosis, and in the [[blood vessels]], such as [[arteriosclerosis]] in both the [[afferent]] and the [[efferent]] renal arterioles. Findings on histopathological analysis may be evident very early in diabetes, but are often clinically present approximately 15 years after the onset of metabolic abnormalities. Diabetic nephropathy (DN) is characterized by the presence of [[proteinuria]] or decreased renal function in patients with diabetes mellitus. Diabetic nephropathy may be early or overt.
==Pathophysiology==
The pathophysiology of diabetic nephropathy is related to chronic [[hyperglycemia]]. However, it is not completely understood. It is thought to be related to the effects of the following:
*[[Hemodynamic]] factors: the imbalance between the arteriolar resistance of the [[afferent]] and [[efferent]] arterioles results in increased [[Hydrostatic pressure|glomerular hydrostatic pressure]] and hyperfiltration. These effects are mediated by:
**Activation of the [[RAS|renin-angiotensin-aldosterone (RAS]]) system: results in [[efferent]] [[vasoconstriction]]. In addition, the high levels of [[ACE]] are associated with greater [[albuminuria]] and [[nephropathy]].
**Increased levels of [[endothelin|endothelin I]] and urotensin II contribute to [[vasoconstriction]].
**Dysregulation of the amounts of [[nitric oxide]] ([[NO]]) and [[nitric oxide synthase]] ([[NOS]]).
*Metabolic factors: [[oxidative stress]] and the production of [[reactive oxygen species]] (ROS) contribute to the damage seen in diabetic nephropathy.
*[[Growth factors]]: TGF-ß and its downstream product, CTGF, induce [[extracellular matrix]] (ECM) formation. In addition, they mediate the [[fibrosis]] seen in the later stages of diabetic nephropathy.
*[[Inflammation]]: much of the pathogenesis of diabetic nephropathy is related to the production of proinflammatory [[cytokines]] and the recruitment of [[macrophages]] and [[T-lymphocytes]].


==Pathophysiology==
=== Early disease ===
* The first renal abnormality seen in patients with diabetic nephropathy is [[hyperfiltration]] and intraglomerular hypertension.
The onset of diabetic nephropathy generally occurs at least 15 years after the onset of diabetes mellitus. The pathogenesis of diabetic nephropathy occurs in distinct stages. Early pathogenesis - which may start as early as 2 years after the onset of diabetes -  may include no visible lesions with mild ''global'' and ''diffuse'' hypertrophy of the renal glomeruli only. This process is called "[[Glomerular basement membrane|GBM]] thickening", a linear process that is caused by the accumulation of [[extracellular matrix]].<ref name="pmid11978659">{{cite journal| author=Drummond K, Mauer M, International Diabetic Nephropathy Study Group| title=The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. | journal=Diabetes | year= 2002 | volume= 51 |issue= 5 | pages= 1580-7 | pmid=11978659 | doi= | pmc= |url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11978659  }} </ref> These changes may not be detectable by [[light microscopy]] and require [[electron microscopy]] to identify. When the accumulation of the [[extracellular matrix]] becomes significant, pathological changes on light microscopy will be evident, typically first seen 5 years after onset of [[Type 1 diabetes mellitus|type 1 diabetes]] and usually occurs at a faster frequency after 15 years of onset. While an increase in cellularity is often observed early in the disease, mesangial expansion without hypercellularity is common as the disease further progresses. Disorganized mesangial expansion - the hallmark of diabetic nephropathy - is not a linear process and is in fact the result of a vicious circle that is characterized by the presence of frequently mesangiolysis followed by the formation of micro-aneurysms and balloon formation of [[glomeruli]], hyaline accumulation, and mesangial repair with concomitant thickening of the [[Glomerular basement membrane|GBM]] lamina densa.
* [[Microalbuminuria]] ([[serum albumin]] level:30 - 300 mg/dl) is the earliest abnormality noted in the urine. This change first appears approximately 5 years after diagnosis of [[diabetes mellitus]]. Although uncontrolled [[systemic hypertension]], sustained high [[blood glucose]] levels and high [[serum cholesterol]] levels contribute to faster progression of damage to [[nephrons]] and earlier appearance of [[albumin]] in urine.
 
* This [[microalbuminuria]] is not detectable on routine protein dipstick.
=== Advanced disease ===
* As the nephropathy progresses, systemic blood pressure more [[albumin]] is filtered across the glomerular membrane and ultimately reaches [[nephrotic syndrome|nephrotic]] range within the next 5 to 10 years.
Advanced diabetic nephropathy is typically seen approximately 15 years after the onset of diabetes type I. It is characterized by the abundant sclerosis of the mesangium and mesangial expansion in an irregular nodular (round/oval) pattern, called Kimmelstiel-Wilson nodules.<ref name="pmid21659756">{{cite journal|author=Najafian B, Alpers CE, Fogo AB| title=Pathology of human diabetic nephropathy.|journal=Contrib Nephrol | year= 2011 | volume= 170 | issue=  | pages= 36-47 |pmid=21659756 |doi=10.1159/000324942 | pmc= |url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21659756  }} </ref> These nodules are acellular or pauci-cellular nodules with a lamellated appearance that stain positively by silver methenamine stain.<ref name="pmid21659756">{{cite journal|author=Najafian B, Alpers CE, Fogo AB| title=Pathology of human diabetic nephropathy.| journal=Contrib Nephrol | year= 2011 |volume= 170 | issue=  | pages= 36-47 |pmid=21659756 | doi=10.1159/000324942 | pmc=|url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21659756  }} </ref> They are a non-specific finding in diabetic nephropathy but are frequently found in glomerular tufts in up to 25% of patients with advanced diabetic nephropathy.<ref name="pmid21659756">{{cite journal|author=Najafian B, Alpers CE, Fogo AB| title=Pathology of human diabetic nephropathy.|journal=Contrib Nephrol | year= 2011 | volume= 170 | issue=  | pages= 36-47 |pmid=21659756 |doi=10.1159/000324942 | pmc= |url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21659756  }} </ref> Kimmelsteil-Wilson nodules may also be found in other disease entities, such as [[multiple myeloma]] and other gammopathies, [[Membranoproliferative glomerulonephritis|membranoproliferative glomerulopathies]], [[post-infectious glomerulonephritis]], [[amyloidosis]], as well as [[Nodular glomerulosclerosis|idiopathic nodular glomerulosclerosis]] in patients with no renal disease.
* Accumulation of glycosylated proteins also damage the renal tubular epithelium causing [[type IV renal tubular acidosis]], resulting in [[hyperkalemia]].
 
Hyalinosis, defined as the exudation of hyaline material (usually lipid particles) between the [[basement membrane]] of [[Bowman's capsule]] and the parietal epithelium.<ref name="pmid21659756">{{cite journal| author=Najafian B, Alpers CE, Fogo AB| title=Pathology of human diabetic nephropathy. |journal=Contrib Nephrol | year= 2011 | volume= 170 | issue=  | pages= 36-47 | pmid=21659756 |doi=10.1159/000324942 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21659756  }} </ref> Meanwhile, the irreversible loss of [[podocytes]] plays a crucial role in the disease pathogenesis and the clinical finding of [[proteinuria]] in patients with diabetic nephropathy. [[Podocyte]] injury first starts with widening of the [[podocyte]] foot processes with consequent detachment from the [[Glomerular basement membrane|GBM]].<ref name="pmid17536064">{{cite journal| author=Toyoda M, Najafian B, Kim Y, Caramori ML, Mauer M| title=Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. | journal=Diabetes | year= 2007 | volume= 56 | issue= 8 |pages= 2155-60 | pmid=17536064 | doi=10.2337/db07-0019 | pmc= |url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17536064  }} </ref> As [[podocytes]] are lost, glomerulotubular junctions are exposed to further injury and formation of atubular [[glomeruli]]. Typically, patients with diabetic nephropathy do not demonstrate any specific findings on [[immunofluorescence]], but [[IgG]] deposition is common in these patients. The presence of [[IgG]] is not believed to be a cause of the disease, but rather as a by-product due to the presence of an abnormal ''sticky'' [[Glomerular basement membrane|GBM]].<ref name="pmid21659756">{{cite journal| author=Najafian B, Alpers CE, Fogo AB| title=Pathology of human diabetic nephropathy. | journal=Contrib Nephrol | year= 2011 | volume= 170 | issue=  |pages= 36-47 | pmid=21659756 | doi=10.1159/000324942 | pmc= |url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21659756  }} </ref>
 
==Gross Pathology==
In the early stages of diabetic nephropathy, there is renal [[hypertrophy]], due to expansion of the [[glomeruli]]. The resultant increase in [[kidney]] size is due to enlargement of the [[mesangium]], the [[glomerular basement membrane]], as well as the [[afferent]] and [[efferent]] renal [[arterioles]]. However, in the later stages of diabetic nephropathy and [[ESRD]], the [[kidneys]] become small and [[atrophy|atrophic]], with diffuse [[glomerulosclerosis]].
 
==Microscopic Pathology==
{| style="float: right; width: 350px;"
| [[Image:Nodular glomerulosclerosis.jpeg|right|400px|thumb|Nodular glomerulosclerosis in two kidney glomeruli - Public Domain, https://commons.wikimedia.org/w/index.php?curid=2740312]]
|}
===Glomerular Lesions<ref name="pmid21659756">{{cite journal| author=Najafian B, Alpers CE, Fogo AB| title=Pathology of human diabetic nephropathy. | journal=Contrib Nephrol | year= 2011 |volume= 170 | issue=  | pages= 36-47 | pmid=21659756 | doi=10.1159/000324942 | pmc=|url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21659756  }} </ref>===
====''Light Microscopy''====
*[[Glomerular]] [[hypertrophy]] and possible hypercellularity
*Thickened capillary [[Basement membrane|basement membranes]]
*Diffuse irregular [[Mesangial cell|mesangial]] expansion and [[sclerosis]]
*Nodular mesangial [[sclerosis]]
*Mesangiolysis
*Capillary micro-aneurysms
*Hyaline deposition
====''Immunofluorescence''====
*Linear staining of capillary [[basement membrane]] for [[IgG]]
*Linear staining of capillary [[basement membrane]] for [[albumin]]
====''Electron Microscopy''====
*Thickened [[basement membranes]]
*Increased mesangial [[extracellular matrix]] and possible hypercellularity
*Non-amyloidotic [[extracellular matrix]]
*[[Podocyte]] loss
 
===Lesions of Tubules & Interstitium<ref name="pmid21659756">{{cite journal| author=Najafian B, Alpers CE, Fogo AB| title=Pathology of human diabetic nephropathy. | journal=Contrib Nephrol|year= 2011 | volume= 170 | issue=  | pages= 36-47 | pmid=21659756 | doi=10.1159/000324942 | pmc=|url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21659756  }} </ref>===
====''Light Microscopy''====
*[[Atrophy]]
*Thickened tubular [[basement membrane]]
*Interstitial [[fibrosis]]
====''Immunofluorescence''====
*Linear staining of tubular [[basement membrane]] for [[IgG]]
*Linear staining of tubular [[basement membrane]] for [[albumin]]
====''Electron Microscopy''====
*Thickened tubular [[Basement membrane|basement membranes]]
*Increased presence of interstitial [[collagen]]
*Tubular [[atrophy]]
===Blood Vessels<ref name="pmid21659756">{{cite journal| author=Najafian B, Alpers CE, Fogo AB|title=Pathology of human diabetic nephropathy. | journal=Contrib Nephrol | year= 2011 | volume= 170 | issue=  | pages= 36-47 | pmid=21659756 | doi=10.1159/000324942 | pmc=|url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21659756  }} </ref>===
====''Light Microscopy''====
*Hyalinosis of [[Afferent arterioles|afferent]] and [[efferent arterioles]]
*Intimal [[sclerosis]]
====''Immunofluorescence''====
*No specific changes
====''Electron Microscopy''====
*Subendothelial and transmural hyaline arterial deposition in small [[arteries]] and [[arterioles]]


==References==
==References==


{{Reflist|2}}
{{Reflist|2}}
 
<references />
[[Category:Kidney diseases]]
[[Category:Angiology]]
[[Category:Diabetes]]
[[Category:Disease]]
 
{{WH}}
{{WS}}

Latest revision as of 13:47, 26 July 2018

Title
https://https://www.youtube.com/watch?v=LtdWg4ygm_E&t=9s%7C350}}

Diabetic nephropathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Diabetic nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Diabetic nephropathy pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Diabetic nephropathy pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Diabetic nephropathy pathophysiology

CDC on Diabetic nephropathy pathophysiology

Diabetic nephropathy pathophysiology in the news

Blogs on Diabetic nephropathy pathophysiology

Directions to Hospitals Treating Diabetic nephropathy

Risk calculators and risk factors for Diabetic nephropathy pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dima Nimri, M.D. [2]

Overview

The hallmark of diabetic nephropathy is mesangial expansion. Nonetheless, diabetic nephropathy is characterized by the presence of abnormalities in the glomeruli, such as glomerular hypertrophy, in the tubules and interstitium, such as tubular atrophy and interstitial fibrosis, and in the blood vessels, such as arteriosclerosis in both the afferent and the efferent renal arterioles. Findings on histopathological analysis may be evident very early in diabetes, but are often clinically present approximately 15 years after the onset of metabolic abnormalities. Diabetic nephropathy (DN) is characterized by the presence of proteinuria or decreased renal function in patients with diabetes mellitus. Diabetic nephropathy may be early or overt.

Pathophysiology

The pathophysiology of diabetic nephropathy is related to chronic hyperglycemia. However, it is not completely understood. It is thought to be related to the effects of the following:

Early disease

The onset of diabetic nephropathy generally occurs at least 15 years after the onset of diabetes mellitus. The pathogenesis of diabetic nephropathy occurs in distinct stages. Early pathogenesis - which may start as early as 2 years after the onset of diabetes - may include no visible lesions with mild global and diffuse hypertrophy of the renal glomeruli only. This process is called "GBM thickening", a linear process that is caused by the accumulation of extracellular matrix.[1] These changes may not be detectable by light microscopy and require electron microscopy to identify. When the accumulation of the extracellular matrix becomes significant, pathological changes on light microscopy will be evident, typically first seen 5 years after onset of type 1 diabetes and usually occurs at a faster frequency after 15 years of onset. While an increase in cellularity is often observed early in the disease, mesangial expansion without hypercellularity is common as the disease further progresses. Disorganized mesangial expansion - the hallmark of diabetic nephropathy - is not a linear process and is in fact the result of a vicious circle that is characterized by the presence of frequently mesangiolysis followed by the formation of micro-aneurysms and balloon formation of glomeruli, hyaline accumulation, and mesangial repair with concomitant thickening of the GBM lamina densa.

Advanced disease

Advanced diabetic nephropathy is typically seen approximately 15 years after the onset of diabetes type I. It is characterized by the abundant sclerosis of the mesangium and mesangial expansion in an irregular nodular (round/oval) pattern, called Kimmelstiel-Wilson nodules.[2] These nodules are acellular or pauci-cellular nodules with a lamellated appearance that stain positively by silver methenamine stain.[2] They are a non-specific finding in diabetic nephropathy but are frequently found in glomerular tufts in up to 25% of patients with advanced diabetic nephropathy.[2] Kimmelsteil-Wilson nodules may also be found in other disease entities, such as multiple myeloma and other gammopathies, membranoproliferative glomerulopathies, post-infectious glomerulonephritis, amyloidosis, as well as idiopathic nodular glomerulosclerosis in patients with no renal disease.

Hyalinosis, defined as the exudation of hyaline material (usually lipid particles) between the basement membrane of Bowman's capsule and the parietal epithelium.[2] Meanwhile, the irreversible loss of podocytes plays a crucial role in the disease pathogenesis and the clinical finding of proteinuria in patients with diabetic nephropathy. Podocyte injury first starts with widening of the podocyte foot processes with consequent detachment from the GBM.[3] As podocytes are lost, glomerulotubular junctions are exposed to further injury and formation of atubular glomeruli. Typically, patients with diabetic nephropathy do not demonstrate any specific findings on immunofluorescence, but IgG deposition is common in these patients. The presence of IgG is not believed to be a cause of the disease, but rather as a by-product due to the presence of an abnormal sticky GBM.[2]

Gross Pathology

In the early stages of diabetic nephropathy, there is renal hypertrophy, due to expansion of the glomeruli. The resultant increase in kidney size is due to enlargement of the mesangium, the glomerular basement membrane, as well as the afferent and efferent renal arterioles. However, in the later stages of diabetic nephropathy and ESRD, the kidneys become small and atrophic, with diffuse glomerulosclerosis.

Microscopic Pathology

Nodular glomerulosclerosis in two kidney glomeruli - Public Domain, https://commons.wikimedia.org/w/index.php?curid=2740312

Glomerular Lesions[2]

Light Microscopy

Immunofluorescence

Electron Microscopy

Lesions of Tubules & Interstitium[2]

Light Microscopy

Immunofluorescence

Electron Microscopy

Blood Vessels[2]

Light Microscopy

Immunofluorescence

  • No specific changes

Electron Microscopy

  • Subendothelial and transmural hyaline arterial deposition in small arteries and arterioles

References

  1. Drummond K, Mauer M, International Diabetic Nephropathy Study Group (2002). "The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes". Diabetes. 51 (5): 1580–7. PMID 11978659.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Najafian B, Alpers CE, Fogo AB (2011). "Pathology of human diabetic nephropathy". Contrib Nephrol. 170: 36–47. doi:10.1159/000324942. PMID 21659756.
  3. Toyoda M, Najafian B, Kim Y, Caramori ML, Mauer M (2007). "Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy". Diabetes. 56 (8): 2155–60. doi:10.2337/db07-0019. PMID 17536064.